A Phase 2 interventional study of Continuous infusion high-dose MCI-186 and Continuous infusion low-dose MCI-186 in Acute Ischemic Stroke, sponsored by Shionogi. Terminated at 45 sites in Japan. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-07-16.
Sponsored by Shionogi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Ischemic Stroke with a site in Japan — 7 open to participants now, 11 under way, 3 of them phase 3. Ischemic Stroke · Japan.
Among the 43 studies in Ischemic Stroke with a site in Japan, this one is the 33rd largest by enrollment of the 35 interventional ones that give a count, is one of 5 that started in 2017, is one of 8 in phase 2, and was the 21st registered.
2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.
Browse Ischemic Stroke studies →7 of the 43 studies in Ischemic Stroke with a site in Japan are open now. Recruiting first, the newest first:
Takeda · Sites in Japan, United States, Belgium and 7 more countries
Ages 18+
Astellas Pharma Inc · Sites in Japan
Ages 18–80
Osaka University · Sites in Japan
Hyogo Medical University · Sites in Japan, Thailand, Vietnam
Ages 18–84
Nippon Medical School · Sites in Japan
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.
This study: 20 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 10 · Phase 4 5
First in 2004; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is below the median of 120 across 1,781 interventional studies indexed under Ischemic Stroke.
Median enrollment 270 across the 35 interventional studies, 650 across the 8 observational. Of the 28 that completed or were terminated, 10 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 43 have an industry lead sponsor. The 10 most frequent:
Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.
Shionogi has 3 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
2 of the studies in Ischemic Stroke with a site in Japan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02251665National Cerebral and Cardiovascular Center, JapanNational Cerebral and Cardiovascular Center (NCVC) Stroke Registry | 2027-03 |
| NCT07819526Osaka UniversityAcute Ischemic Stroke in Patients With Active Cancer | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies in Ischemic Stroke with a site in Japan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To investigate the efficacy and safety of MCI-186 (bolus followed by continuous infusion) in acute ischemic stroke patients through a double-blind, parallel-group comparison with the existing MCI-186 dosing regimen (administration twice daily for 14 days) as the control.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
High-dose MCI-186 will be administered as a bolus, and then as a continuous infusion. In addition, a placebo will be administered as an intravenous infusion twice a day over 30 minutes.
Drug: Continuous infusion high-dose MCI-186 · Drug: Approved dosing regimen placebo
Low-dose MCI-186 will be administered as a bolus, and then as a continuous infusion. In addition, a placebo will be administered as an intravenous infusion twice a day over 30 minutes.
Drug: Continuous infusion low-dose MCI-186 · Drug: Approved dosing regimen placebo
A placebo will be administered as a bolus, and then as a continuous infusion. In addition, MCI-186 30 mg will be administered as an intravenous infusion twice a day over 30 minutes.
Drug: Continuous infusion placebo · Drug: Approved dosing regimen MCI-186
intravenous injection
intravenous injection
intravenous injection
intravenous injection
intravenous injection
Number of Participants With National Institutes of Health Stroke Scale (NIHSS) Score Improved.
NIHSS is a scale to objectively quantify the neurologic impairment caused by a stroke. Possible scores range from 0 (no stroke symptoms) to 40(severe stroke).
Time frame: Baseline up to Day 7
Comparison of National Institutes of Health Stroke Scale (NIHSS)
NIHSS is a scale used to objectively quantify the neurologic impairment caused by a stroke. Possible scores range from 0 (no stroke symptoms) to 40 (severe stroke).
Time frame: Day 14, at discharge(from Day15 to after 3 months) and after 3 months
Number of Participants With Modified Rankin Scale (mRS) 0-1 at Each Evaluations
mRS is a scale for measuring the degree of disability caused by a stroke. Possible scores range from Grade 0 (no symptoms) to Grade 6 (death). Number of Participants with Modified Rankin Scale (mRS) 0-1 are evaluated.
Time frame: at discharge(from Day15 to after 3 months) and after 3 months
Comparison of Barthel Index (BI)
BI is a scale for measuring performance in Activities of Daily Living (ADL). Possible scores range from 0 (worst) to 100 (best).
Time frame: at discharge(from Day15 to after 3 months) and after 3 months
Comparison of Functional Independence Measure (FIM)
FIM is a scale used to evaluate the functional status. Possible scores range from 18 (worst) to 126 (best).
Time frame: at discharge(from Day15 to after 3 months) and after 3 months
| Milestone | Continuous Infusion High-dose Group (Group H) | Continuous Infusion Low-dose Group (Group L) | Approved Dosing Regimen Group (Control Group) |
|---|---|---|---|
| Started | 7 | 4 | 6 |
| Completed | 4 | 1 | 5 |
| Not completed | 3 | 3 | 1 |
| Withdrew: Physician decision | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 3 | 2 | 0 |
| Withdrew: One subject of control group who discontinued prior to initiation of study drug administration. | 0 | 0 | 1 |
NIHSS is a scale to objectively quantify the neurologic impairment caused by a stroke. Possible scores range from 0 (no stroke symptoms) to 40(severe stroke).
| Participants | Continuous Infusion High-dose Group (Group H) | Continuous Infusion Low-dose Group (Group L) | Approved Dosing Regimen Group (Control Group) |
|---|---|---|---|
| Day 1 | 0 | 0 | 0 |
| Day 2 | 2 | 0 | 1 |
| Day 3 | 2 | 0 | 1 |
| Day 4 | 2 | 0 | 1 |
| Day 5 | 2 | 0 | 1 |
| Day 6 | 3 | 1 | 1 |
| Day 7 | 3 | 1 | 1 |
NIHSS is a scale used to objectively quantify the neurologic impairment caused by a stroke. Possible scores range from 0 (no stroke symptoms) to 40 (severe stroke).
| units on a scale | Continuous Infusion High-dose Group (Group H) | Continuous Infusion Low-dose Group (Group L) | Approved Dosing Regimen Group (Control Group) |
|---|---|---|---|
| Day 14 | 3.7 ± 6.1 | 2.5 ± 2.1 | 2.8 ± 1.5 |
| at discharge | 3.5 ± 5.1 | 2.0 ± 1.4 | 3.3 ± 1.5 |
| after 3 months | 3.3 ± 3.2 | 0.0 ± NA | 1.8 ± 0.8 |
mRS is a scale for measuring the degree of disability caused by a stroke. Possible scores range from Grade 0 (no symptoms) to Grade 6 (death). Number of Participants with Modified Rankin Scale (mRS) 0-1 are evaluated.
| Participants | Continuous Infusion High-dose Group (Group H) | Continuous Infusion Low-dose Group (Group L) | Approved Dosing Regimen Group (Control Group) |
|---|---|---|---|
| at discharge | 4 | 1 | 3 |
| after 3 months | 2 | 1 | 3 |
BI is a scale for measuring performance in Activities of Daily Living (ADL). Possible scores range from 0 (worst) to 100 (best).
| units on a scale | Continuous Infusion High-dose Group (Group H) | Continuous Infusion Low-dose Group (Group L) | Approved Dosing Regimen Group (Control Group) |
|---|---|---|---|
| at discharge | 80 ± 36.7 | 72.5 ± 38.9 | 83.3 ± 28.9 |
| after 3 months | 90 ± 17.3 | 100 ± NA | 100 ± 0 |
FIM is a scale used to evaluate the functional status. Possible scores range from 18 (worst) to 126 (best).
| units on a scale | Continuous Infusion High-dose Group (Group H) | Continuous Infusion Low-dose Group (Group L) | Approved Dosing Regimen Group (Control Group) |
|---|---|---|---|
| at discharge | 102.2 ± 33.8 | 91.5 ± 41.7 | 121.8 ± 4.1 |
| after 3 months | 93.7 ± 54.3 | 125.0 ± NA | 123.4 ± 2.5 |
Collected over Adverse events occurring in subjects up to 3 months after the start of investigational product treatment were investigated.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Continuous Infusion High-dose Group (Group H) | 0/7 (0%) | 1/7 (14.3%) | 6/7 (85.7%) |
| Continuous Infusion Low-dose Group (Group L) | 0/3 (0%) | 1/3 (33.3%) | 2/3 (66.7%) |
| Approved Dosing Regimen Group (Control Group) | 0/5 (0%) | 1/5 (20%) | 4/5 (80%) |
| Event | Continuous Infusion High-dose Group (Group H) | Continuous Infusion Low-dose Group (Group L) | Approved Dosing Regimen Group (Control Group) |
|---|---|---|---|
| Pneumonia aspirationRespiratory, thoracic and mediastinal disorders | 0/7 | 1/3 | 0/5 |
| Hepatic massHepatobiliary disorders | 0/7 | 0/3 | 1/5 |
| Transient ischaemic attackNervous system disorders | 1/7 | 0/3 | 0/5 |
| Event | Continuous Infusion High-dose Group (Group H) | Continuous Infusion Low-dose Group (Group L) | Approved Dosing Regimen Group (Control Group) |
|---|---|---|---|
| ConstipationGastrointestinal disorders | 3/7 | 1/3 | 1/5 |
| Urinary tract infectionInfections and infestations | 0/7 | 1/3 | 0/5 |
| Chondrocalcinosis pyrophosphateMusculoskeletal and connective tissue disorders | 0/7 | 1/3 | 0/5 |
| DeliriumPsychiatric disorders | 1/7 | 1/3 | 0/5 |
| Pneumonia aspirationRespiratory, thoracic and mediastinal disorders | 0/7 | 1/3 | 0/5 |
| DermatitisSkin and subcutaneous tissue disorders | 0/7 | 1/3 | 0/5 |
| Eczema asteatoticSkin and subcutaneous tissue disorders | 0/7 | 1/3 | 0/5 |
| PsoriasisSkin and subcutaneous tissue disorders | 0/7 | 1/3 | 0/5 |
| UrticariaSkin and subcutaneous tissue disorders | 0/7 | 1/3 | 0/5 |
| HeadacheNervous system disorders | 2/7 | 0/3 | 1/5 |
Among the randomised of 17 subjects, the baseline participants consisted of 15 subjects, excluding 1 who withdrew their consent after randomization and 1 who discontinued prior to initiation of study drug administration.
| Age, Continuous(years) | Continuous Infusion High-dose Group (Group H) | Continuous Infusion Low-dose Group (Group L) | Approved Dosing Regimen Group (Control Group) | Total |
|---|---|---|---|---|
| Mean | 76.3 ± 6.8 | 75.7 ± 7.4 | 64.4 ± 11.2 | 72.2 ± 9.8 |
| Sex: Female, Male(Participants) | Continuous Infusion High-dose Group (Group H) | Continuous Infusion Low-dose Group (Group L) | Approved Dosing Regimen Group (Control Group) | Total |
|---|---|---|---|---|
| Female | 6 | 2 | 3 | 11 |
| Male | 1 | 1 | 2 | 4 |
| Race/Ethnicity, Customized(Participants) | Continuous Infusion High-dose Group (Group H) | Continuous Infusion Low-dose Group (Group L) | Approved Dosing Regimen Group (Control Group) | Total |
|---|---|---|---|---|
| Japanese | 7 | 3 | 5 | 15 |
| Non-Japanese | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2017 to primary completion in May 2018, 5 months.
Results were first posted in Jan 2025, 6 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.